| Literature DB >> 27290668 |
Sujan Dilly Penchala1, Sandra Fawcett2, Laura Else2, Deirdre Egan2, Alieu Amara2, Emilie Elliot3, Elizabeth Challenger2, David Back2, Marta Boffito3, Saye Khoo2.
Abstract
Dolutegravir and Elvitegravir belongs to a class of integrase inhibitors which has recently been approved by the FDA for the treatment of HIV-infection. Elvitegravir and its co-administered booster drug, Cobicistat, has shown the potential to be a candidate for a one pill once a day regimen and is currently a component of many clinical trials. A sensitive LC-MS/MS method has been developed and validated for the simultaneous determination of these three drugs in human plasma. A liquid- liquid extraction was used as a sample preparation technique using 100μL of plasma. The method was validated from 10 to 4000ng/mL for Dolutegravir, Elvitegravir and Cobicistat. Chromatography was performed on XBridge C18 2.1mm×50mm column, using an 80:20 methanol/water mobile phase containing 0.1% formic acid on a gradient program. This method was successfully applied for ongoing clinical trials.Entities:
Keywords: Cobicistat; Dolutegravir; Elvitegravir; LC–MS/MS; Method validation
Mesh：
Substances：
Year: 2016 PMID： 27290668 DOI： 10.1016/j.jchromb.2016.05.040
Source DB: PubMed Journal: J Chromatogr B Analyt Technol Biomed Life Sci ISSN： 1570-0232 Impact factor: 3.205